

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

SW579

RRID:CVCL_3603

Type: Cell Line

Proper Citation

RRID:CVCL_3603

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3603

Proper Citation: RRID:CVCL_3603

Description: Cell line SW579 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Thyroid gland squamous cell carcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:1516062](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:29066502](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31443247](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW579

Synonyms: SW-579, SW 579

Cross References: CLO:CLO_0009220, ArrayExpress:E-MTAB-2770, ATCC:HTB-107, BCRC:60412, BioSample:SAMN10988339, cancercellines:CVCL_3603, CCRID:1101HUM-PUMC000264, CCRID:3101HUMTCHu125, Cell_Model_Passport:SIDM01167, CLS:300346, Cosmic:1005454, Cosmic:1006467, Cosmic:1017791, Cosmic:1041672, Cosmic:1094773, Cosmic:1339924, DepMap:ACH-000163, GEO:GSM887676, GEO:GSM888768, GEO:GSM1374931, GEO:GSM1374932, IARC_TP53:1308, IGRhCellID:SW579, IZSLER:BS TCL 121, KCB:KCB 2013004YJ,

LiGeA:CCLE_771, PharmacDB:SW579_1540_2019, Progenetix:CVCL_3603,
Wikidata:Q54971179

ID: CVCL_3603

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260920T005911+0000

Ratings and Alerts

No rating or validation information has been found for SW579.

No alerts have been found for SW579.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.